Pfizer-BioNTech COVID-19 Vaccine Protects Against Severe Illness Resulting from the Omicron Variant
A study conducted at Sheba Medical Center found that three doses of the COVID-19 vaccine provide significant protection against the Omicron variant
Sheba’s Prof. Gili Regev-Yochay Has Been Named the Latest Laureate of the Paul Harris Fellowship
Senior Sheba Physician Honored for Her Role in the Fight Against COVID-19. Click Here to Learn More.
Prof. Gili Regev-Yochay: “Israel Has Achieved Herd Immunity Against COVID-19”
Israel Marks Yet Another Landmark in the Battle Against COVID-19. Click Here to Learn More:
Israel Dispatches a Medical Aid Delegation to COVID-19 Stricken Uruguay
The delegation comprises Sheba Medical Center physicians and experts with extensive experience in combating the virus
Experts Say Israel May Have Achieved Herd Immunity Against COVID-19
Click here to learn why “Israel is expected to be a very safe place for travelers” while the COVID-19 pandemic still rages on around the world.
Antibody Levels Remain High Two Months After Receiving the Second Dose of the COVID-19 Vaccine
According to the latest data, the Pfizer-BioNTech COVID-19 vaccine remains effective for at least two months after receiving the second jab. Click here to learn more.
Dedicated COVID-19 Emergency Room and Children’s Ward at Sheba Medical Center Closed as Infection Rates Continue to Drop Across Israel
Israel leads the world in vaccines per capita, with more than 54% of the population fully inoculated
New Sheba Study Indicates That Ivermectin Can Reduce the Length of COVID-19 Infection
Could Ivermectin Help Break the COVID-19 Transmission Chain? Click Here to Read About a New Sheba Study:
Positive Initial Results for Novel COVID-19 Drug Molnupiravir First Tested at Sheba
Initial clinical trial results indicate the efficacy of the novel COVID-19 drug Molnupiravir, first tested at Sheba.
